Valuation: Unicycive Therapeutics, Inc.

Market Cap 100M 89.26M 82.96M 75.46M 142M 9.47B 145M 997M 390M 4.94B 375M 367M 15.81B P/E 2026 *
-2.84x
P/E 2027 * 1.96x
Enterprise Value 100M 89.26M 82.96M 75.46M 142M 9.47B 145M 997M 390M 4.94B 375M 367M 15.81B EV / Sales 2026 *
73x
EV / Sales 2027 * 0.67x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * 57.9%
1 day-2.97%
1 week-11.79%
Current month-23.54%
1 month-23.78%
3 months-28.49%
6 months-48.49%
Current year-37.78%
1 week 3.56
Extreme 3.56
4.11
1 month 3.56
Extreme 3.56
4.97
Current year 3.56
Extreme 3.56
8.74
1 year 3.56
Extreme 3.56
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
31.3
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 18/08/2016
Director of Finance/CFO 64 01/03/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Chairman 53 18/08/2016
Director/Board Member 58 01/01/2018
Director/Board Member 58 06/09/2023
Date Insider Type Main position Quantity % Market Cap. Importance
14/5/26 Free

Chief Operating Officer

169,500 0.6716%
14/5/26 Free

Executive/Senior Manager

169,500 0.6716%
14/5/26 Free

Chief Financial Officer

169,500 0.6716%
Change 5-day change 1-year change 3-year change Capi.($)
-2.97%-11.79%-25.21%-58.16% 103M
+0.21%-4.63%+55.34%+71.32% 68.92B
+1.66%-9.54%+10.39%+60.04% 51.9B
+3.14%+4.61%+15.36%+44.42% 48.73B
+3.45%+4.70%+33.44%+35.96% 43.13B
-2.20%+0.61%+281.88%+532.76% 41.48B
+6.43%+6.84%+18.32%+109.23% 39.96B
+1.28%-0.76%+12.67%+45.10% 30.6B
-2.21%-14.22%+40.33%-0.94% 26.01B
+1.74%-2.02%-13.55%-12.92% 22.27B
Average +1.05%-4.34%+42.90%+82.68% 37.31B
Weighted average by Cap. +1.58%-3.12%+53.87%+105.26%

Financials

2026 *2027 *
Net sales 1.37M 1.22M 1.14M 1.03M 1.95M 130M 1.98M 13.65M 5.34M 67.7M 5.14M 5.03M 217M 150M 133M 124M 113M 212M 14.16B 216M 1.49B 583M 7.39B 561M 549M 23.64B
Net income -35.38M -31.58M -29.35M -26.7M -50.23M -3.35B -51.14M -353M -138M -1.75B -133M -130M -5.6B 57.12M 50.99M 47.39M 43.11M 81.1M 5.41B 82.56M 569M 223M 2.82B 214M 210M 9.03B
Net Debt - -
Projected Income Statement - Annual - Unicycive Therapeutics, Inc.
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
15/10/26 US$3.590 -2.97% 893,143
14/10/26 US$3.700 -0.80% 1,208,828
13/10/26 US$3.730 -7.90% 1,840,063
12/10/26 US$4.050 -1.46% 912,907
09/10/26 US$4.110 +0.98% 551,388
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Unicycive Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.590USD
Average target price
28.40USD
Spread / Average Target
+691.09%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Unicycive Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. UNCY Stock